尼拉帕利与安慰剂治疗复发性卵巢癌的生活质量:ENGOT-OV16/NOVA双盲3期随机对照试验结果
ENGOT-OV16/NOVA试验纳入553例铂类化疗应答的复发性卵巢癌患者,随机接受尼拉帕利(300 mg每日一次)或安慰剂维持治疗,采用FOSI和EQ-5D-5L评估患者报告结局。结果显示尼拉帕利组整体生活质量在治疗及进展前期间保持稳定,与安慰剂组无显著差异;常见3-4级血液学毒性未显著损害生活质量。
要点
- 尼拉帕利维持治疗期间整体生活质量保持稳定,与安慰剂无显著差异。
- 常见3-4级血液学毒性(血小板减少、贫血、中性粒细胞减少)未显著损害生活质量。
核心结论
- 复发性卵巢癌患者铂类应答后接受尼拉帕利维持治疗,治疗期间生活质量与安慰剂相当且保持稳定。
研究设计与样本
- ENGOT-OV16/NOVA为多中心、双盲、3期随机对照试验,在美加欧以107个中心开展。
- 553例复发性卵巢癌铂类应答患者按2:1随机接受尼拉帕利300 mg每日一次或安慰剂维持治疗。
- 按gBRCA突变状态分为两个独立队列,主要终点无进展生存已报告,本分析评估意向治疗人群的患者报告结局。
主要发现
- 尼拉帕利组整体生活质量在治疗及进展前期间保持稳定,与安慰剂组无显著差异。
- 尼拉帕利组除恶心外所有症状随时间保持稳定或改善。
- 尼拉帕利组最常见3-4级毒性为血液学:血小板减少124/367(34%)、贫血93/367(25%)、中性粒细胞减少72/367(20%),失用分析显示这些毒性未显著损害生活质量。
关键数值与推荐
- 尼拉帕利维持剂量为300 mg每日一次。
- 患者报告结局采用FOSI和EQ-5D-5L评估,前14周期每8周收集,之后每12周收集。
临床怎么用
- 对于铂类应答的复发性卵巢癌患者,尼拉帕利维持治疗在延长无进展生存的同时未显著损害生活质量。
- 常见血液学毒性虽发生率高,但未显著影响患者报告的生活质量,支持临床用药决策。
局限性
- 原文未报告本分析的具体局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Quality of life (QOL) has become an important complementary endpoint in cancer clinical studies alongside more traditional assessments (eg, tumour response, progression-free survival, overall survival). Niraparib maintenance treatment has been shown to significantly improve progression-free survival in patients with recurrent ovarian cancer. We aimed to assess whether the benefits of extending progression-free survival are offset by treatment-associated toxic effects that affect QOL. METHODS: The ENGOT-OV16/NOVA trial was a multicentre, double-blind, phase 3, randomised controlled trial done in 107 study sites in the USA, Canada, Europe, and Israel. Patients with recurrent ovarian cancer who were in response to their last platinum-based chemotherapy were randomly assigned (2:1) to receive either niraparib (300 mg once daily) as a maintenance treatment or placebo. Randomisation was stratified based on time to progression after the penultimate platinum-based regimen, previous use of bevacizumab, and best response (complete or partial) to the last platinum-based regimen with permuted-block randomisation (six in each block) using an interactive web response system. The trial enrolled two independent cohorts on the basis of germline BRCA (gBRCA) mutation status (determined by BRACAnalysis Testing, Myriad Genetics, Salt Lake City, UT, USA). The primary endpoint of the trial was progression-free survival, and has already been reported. In this study, we assessed patient-reported outcomes (PROs) in the intention-to-treat population using the Functional Assessment of Cancer Therapy-Ovarian Symptoms Index (FOSI) and European QOL five-dimension five-level questionnaire (EQ-5D-5L). We collected PROs from trial entry every 8 weeks for the first 14 cycles and every 12 weeks thereafter. If a patient discontinued, we collected PROs at discontinuation and during a postprogression visit 8 weeks (plus or minus 2 weeks) later. We assessed the effect of haematological toxic effects on QOL with disutility analyses of the most common grade 3-4 adverse events (thrombocytopenia, anaemia, and neutropenia) using a mixed model with histology, region, previous treatment, age, planned treatment, and baseline score as covariates. This study is registered with ClinicalTrials.gov, number NCT01847274. FINDINGS: Between Aug 28, 2013, and June 1, 2015, 553 patients were enrolled and randomly assigned to receive niraparib (n=138 in the gBRCAmut cohort, n=234 in the non-gBRCAmut cohort) or placebo (n=65 in the gBRCAmut cohort, n=116 in the non-gBRCAmut cohort). The mean FOSI score at baseline was similar between the two groups (range between 25·0-25·6 in the two groups). Overall QOL scores remained stable during the treatment and preprogression period in the niraparib group; no significant differences were observed between the niraparib and placebo group, and preprogression EQ-5D-5L scores were similar between the two groups in both cohorts (0·838 [0·0097] in the niraparib group vs 0·834 [0·0173] in the placebo group in the gBRCAmut cohort; and 0·833 [0·0077] in the niraparib group vs 0·815 [0·0122] in the placebo group in the non-gBRCAmut cohort). The most common adverse events reported at screening (baseline) were lack of energy (425 [79%]; 97 [18%] reporting severe lack of energy), pain (236 [44%]), and nausea (118 [22%]). All symptoms, except nausea, either remained stable or improved over time in the niraparib group. The most common grade 3 or 4 toxicities observed in the niraparib group were haematological in nature: thrombocytopenia (124 [34%] of 367 patients), anaemia (93 [25%]), and neutropenia (72 [20%]); disutility analyses showed no significant QOL impairment associated with these toxic effects. INTERPRETATION: These PRO data suggest that women who receive niraparib as maintenance treatment for recurrent ovarian cancer after responding to platinum treatment are able to maintain QOL during their treatment when compared with placebo. FUNDING: TESARO.
引用
- Oza AM, Matulonis UA, Malander S, et al. Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial. Lancet Oncol. 2018. PMID: 30026000. doi:10.1016/S1470-2045(18)30333-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。